Modulation of the Pharmacological Activities of Secretory Phospholipase A2 from Crotalus durissus cascavella Induced by Naringin by Santos, ML et al.







Modulation of the Pharmacological Activities of Secretory 
Phospholipase A2 from Crotalus durissus cascavella Induced  
by Naringin  
Marcelo L. Santos 1, Daniela O. Toyama 2, Simone C. B. Oliveira 3, Camila A. Cotrim 3,  
Eduardo B. S. Diz-Filho 3, Fábio H. R. Fagundes 3, Veronica C. G. Soares 3, Ricardo Aparicio 1 
and Marcos H. Toyama 4,* 
1 Laboratório de Biologia Estrutural e Cristalografia, Instituto de Química, UNICAMP, Campinas, 
São Paulo, Brazil 
2 Universidade Presbiteriana Mackenzie, CCBS, São Paulo, Brazil 
3 Departmento de Bioquímica, Instituto de Biologia, UNICAMP, Campinas, São Paulo, Brazil 
4 Laboratório de Macromoléculas Química, UNESP/CLP, São Vicente, São Paulo, Brazil 
* Author to whom correspondence should be addressed; E-Mail: mhtjpn@yahoo.com;  
Tel.: +55 13 3469-7682; Fax: + 55 13 3469-7374. 
Received: 10 December 2010; in revised form: 4 January 2011 / Accepted: 13 January 2011 /  
Published: 18 January 2011 
 
Abstract: In this work we have characterized the action of the naringin, a flavonoid found 
in grapefruit and known for its various pharmacological effects, which include antioxidant, 
blood lipid lowering and anticancer activity, on the structure and biochemical activities of 
a secretory phospholipase A (sPLA2) from Crotalus durissus cascavella, an important 
protein involved in the releasinge of arachidonic acid in phospholipid membranes. sPLA2 
was incubated with naringin (mol:mol) at 37 °C and a discrete reduction in the UV 
scanning signal and a modification of the circular dichroism spectra were observed after 
treatment with naringin, suggesting modifications of the secondary structure of the protein. 
This flavonoid was able to decrease enzymatic activity and some pharmacological effects, 
such as myonecrosis, platelet aggregation, and neurotoxic activity caused by sPLA2, 
however, the inflammatory effect was not affected by naringin. In addition, small angle X-
ray scattering (SAXS) data were collected for sPLA2 and naringin-treated sPLA2 to 
evaluate possible modifications of the protein structure. These structural investigations 
have shown that sPLA2 is an elongated dimer in solution and after treatment with naringin 
a conformational change in the dimeric configuration was observed. Our results suggest 
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that structural modification may be correlated with the loss of enzymatic activity and 
alterations in pharmacological properties. 
Keywords: secretoy phospholipase A2; Crotalus durissus cascavella; naringin; enzymatic 
activity pharmacological effects; small angle X-ray scattering  
 
1. Introduction  
Polyphenolic compounds, such as flavonoids and coumarins, are widely distributed in the plant 
kingdom. Some of these compounds have interesting medicinal properties, exerting anti-
lipoperoxidant, anti-inflammatory, anti-allergic, antiviral, antibacterial, and anticancer effects [1]. 
Recent studies have shown that flavonoids from various plants induce an in vitro dose-dependent 
inhibition of phospholipid hydrolysis mediated by both secretory and cytosolic phospholipasesA2 
(sPLA2 and cPLA2, respectively) [2,3]. Flavonoids assayed in vivo have also shown a significant anti-
inflammatory effect against acute edema induced by carrageenan [4]. 
It has been shown that flavonoids inhibit group I sPLA2s from porcine pancreas and Naja naja in a 
different way from group II sPLA2 from Vipera russelii and Crotalus atrox. The most important 
regions involved in the inhibition of sPLA2 were reported to be hydroxyl groups in the 30- and 40-
positions [5,6]. In addition, Iglesias et al. [7] showed that flavonoids such as morin modify the 
secondary structure of snake venom sPLA2 similarly to sPLA2 when modified with 7-hydroxy 
coumarin [8]. Group II sPLA2 enzymes have been found at inflammatory sites in animal models, as 
well as in synovial fluid from patients with rheumatoid arthritis and various human inflammatory 
diseases in which a correlation between serum sPLA2 levels and disease activity is observed [9,10]. 
Moreover, exogenous administration of sPLA2, such as snake venom sPLA2, induces or exacerbates 
the inflammatory response in animals [11,12]. Structural analyses have revealed that snake venom 
sPLA2s have a similar molecular profile as human secretory PLA2s as well as a conserved catalytic 
site [13]. 
Naringin, hesperidin, and neohesperidin have been described as some of the most abundant 
flavanones found in the Citrus genus, and are responsible for many of the pharmacological properties 
of Citrus flavonoids. These flavanones are particularly interesting because of their antitumoral and 
anti-inflammatory effects, which are linked to the abilities of these compounds to inhibit enzymes 
involved in cell activation [14]. Because sPLA2 from snake venom has been characterized as a pro-
inflammatory inducer, we investigated for the first time the effect of naringin on the edematogenic 
activity of sPLA2 from Crotalus durissus cascavella venom and evaluated other biological and 
pharmacological activities induced by this protein. 
In addition, we also investigated the structural modification induced by this polyphenolic compound 
on the structure of sPLA2. Like other flavonoids, naringin displays a combination of multiple hydroxyl 
groups substituting a ketone-containing flavonoid skeleton and a glycoside group [15]. Reports on 
flavonoid structure−function relationships have demonstrated that antioxidant activities and enzyme 
inhibition are dependent on particular flavonoid structural motifs, such as structure oxidation levels, 
substituents (position, number, and nature of groups), and the presence of glycosylation [14]. Phenolics 




compounds, particularly flavonoids, have been shown to possess important antioxidant activity toward 
free radicals, which are associated with the natural metabolism of aerobic cells [16]. 
To obtain structural information from native sPLA2 and sPLA2 after naringin treatment (sPLA2-
Nar), we used a variety of solution-based techniques. Because small angle X-ray scattering (SAXS) is 
a sensitive technique for analyzing global shape and dimensions of macromolecules in solution [17], 
we employed this method together with molecular modeling, circular dichroism, and bioinformatic 
analysis. 
Several sPLA2 crystallographic studies have been reported describing the main structural features 
of this class of proteins [18] and the correlations with biochemical properties [19]. However, only a 
few reports have been published regarding SAXS analysis of PLA2 [20,21]. In these studies, two 
different oligomeric states were observed for sPLA2s in solution: monomeric for sPLA2 from 
Cerrophidion godmani [20] and dimeric for sPLA2 from Bothrops jararacussu [21]. 
In addition, electrophoresis and spectroscopic studies have suggested that the dimer-like structure in 
solution is common to sPLA2s from other snake venoms [22,23]. Two main different conformations 
were reported using crystallographic models for these dimers: an extended conformation maintained 
by polar interactions formed between the N-terminal helix regions and β-wing residues of each 
monomer, and a compact dimeric organization of the molecules in which the hydrophobic channels are 
buried [24,25]. In solution, however, only the compact conformation has been observed [21]. In this 
paper, we describe a new extended dimer configuration for PLA2 in solution. The low resolution 
model obtained for sPLA2-Nar presents an interesting bending in comparison with the envelopes for 
the native sPLA2 that seem to be correlated with the enzymatic and pharmacological alterations 
observed in our studies. 
2. Results and Discussion  
Chemical treatment of purified sPLA2 with naringin was conducted as described by Iglesias et al. 
[7]. Under these conditions, a discrete decrease in the absorbance of sPLA2-Nar in the wavelength 
region between 270–285 nm (Figure 1a) was observed, which can be attributed to the spectroscopic 
absorption of the aromatic amino acid residues. Amino acid analysis indicated that naringin mainly 
induced modification on the aromatic amino acid residues and histidines, similar to what was reported in 
a previous study with morin [7]. However, we observed slight changes in serine composition (Figure 1b). 
The enzymatic activity of native sPLA2 was virtually abolished by treatment with naringin, which 
showed similar inhibition with p-BPB (Figure 2a; n = 12 experiments; p < 0.05). Native sPLA2 
induced a moderate myotoxic effect (Figure 2b). Previous treatment of sPLA2 with naringin reduced 
the myotoxic effect induced by sPLA2 2-fold, whereas p-bromophenacyl bromide (p-BPB) abolished 
this effect (Figure 2b; n = 6 experiments; P < 0.05). Native sPLA2 induced irreversible neuromuscular 
blockage 70 minutes after injection of the toxin into chick biventer cervicis muscle (Figure 2c), 
whereas sPLA2 treated with naringin induced a moderate blockage when compared to native sPLA2. 
Although both naringin and p-BPB virtually abolished the enzymatic activity of sPLA2, only p-BPB 
treatment irreversibly abolished the neurotoxic effect induced by sPLA2 (Figure 2c; n = 6 
experiments). Platelet aggregation induced by native sPLA2 was strongly reduced by treatment with 
naringin and was abolished by treatment with p-BPB (Figure 2d, n = 4 experiments for each drug). 




Subplantar injections of treated and non-treated sPLA2 (5 µg/paw; n = 5) induced significant acute 
edema (p < 0.05) when compared to the control (PBS) (Figure 3a). Naringin treatment induced a slight 
decrease in edema volume in comparison to native sPLA2, whereas p-BPB strongly reduced this 
effect. On the other hand, previous injection of naringin into the paw affected the edema formation. In 
this new assay, sPLA2-Nar prevented the edema induced by native sPLA2, whereas dexamethasone 
(Dexa), a potent synthetic anti-inflammatory compound, significantly reduced this pharmacological 
effect (Figure 3b). 
Figure 1. (a) Absorption spectra of sPLA2 and modified sPLA2 after incubation with 
naringin at wavelength intervals of 200–300 nm. The amino acid modification was 
analyzed at 280 nm. (b) Amino acid composition of native sPLA2 and sPLA2-Nar. UNK 
indicates unknown or unidentified peak or extra peaks, identified by the PICO-TAG amino 
acid analysis system. 
 




Figure 2. (a) Enzymatic activity. sPLA2-Nar showed a significant decrease compared to 
native sPLA2 and was similar to sPLA2 treated with 4-bromophenacyl bromide (sPLA2-p-
BPB) (n = 12, *P < 0.05). (b) Measurement of creatine kinase (CK) activity from samples 
of animals treated with saline (negative control), native sPLA2 (50 μL, 50 μg), or (sPLA2-
Nar; 50 μL, 50 μg). The last bar represents the effect of sPLA2 treated with p-BPB (50 μL, 
50 μg). Results of creatine kinase levels were expressed as units of enzymatic activity per 
liter (U/L) of blood. Each column represents six animals, and error bars indicate the S.E.M. 
*P < 0.05 compared with sPLA2 native. (c) Neurotoxic effect of sPLA2 and sPLA2-Nar on 
the chick biventer cervicis preparation. Results were expressed as a percent modification of 
twitch tension, and each point represents the mean ± S.E.M. of five preparations.  
* P < 0.05. (d) The washed platelets assay was performed with venous blood collected 
from healthy volunteers. The blood was centrifuged in 3.8% trisodium-citrate for  
10 minutes at 200 g, and the residue was centrifuged again for 20 minutes at 1,500 g. 
Aggregations were performed using native sPLA2 and sPLA2-Nar. 
 




Figure 3. (a) Rat paw edema induced by sPLA2 and sPLA2-Nar showed dose-dependent 
edema with doses of 10 μg/paw, whereas p-BPB treatment virtually abolished the edema 
induced by sPLA2. Observations were conducted at times of 30, 60, 90, 120, 180, and 240 
minutes after injection. Results were expressed as the increase in paw volume (mL) 
calculated by subtracting the basal volume. Each point represents the mean ± S.E.M. of 
four rats and *P < 0.05. (b) Effect of previous injection of dexamethasone or naringin  
(3.0 mg/kg) before injection of native sPLA2. The results were expressed as microliters of 
plasma protein extravasation. Each point represents the mean of four animals, and each 
error bar indicates the S.E.M. *p < 0.05 compared with sPLA2 control. 
 
 
Native sPLA2 showed antibacterial activity against Xanthomonas axonopodis pv passiflora and 
Streptococcus mutans. In both cases, we observed that sPLA2 induced a strong modification of the 
bacterial cell membrane (Figure 4a and 4b). These results suggest that the enzymatic activity of sPLA2 
is important for antibacterial activity, and that inhibition of sPLA2 enzymatic activity by naringin 
virtually abolished its antibacterial activity (Figure 4a and 4b). 
We also performed chemical analyses to better understand the effects observed on pharmacological 
activities. Circular dichroism (CD) measurements of native sPLA2 and sPLA2-Nar showed a 
significant decrease in the CD signal due to treatment with the flavonoid (Figure 5a). This 
spectroscopic alteration suggests that the residues modified by naringin are important secondary 
structural elements. 
Mass spectrometry showed that sPLA2 had an increase in its mass-to-charge ratio after naringin 
treatment in comparison with native sPLA2 (Figure 5b). Similar to the alterations observed in the CD 




spectra, the increase in the molecular mass of sPLA2 is a consequence of the chemical modification 
induced by naringin. 
The effect of naringin treatment on sPLA2 from C. d. cascavella was evaluated with a systematic 
structural study. Despite several attempts to crystallize this protein, it was not possible to obtain a high 
resolution model through X-ray crystallography. Therefore, we employed an alternative strategy to 
acquire useful structural information to interpret the biochemical and pharmacological results obtained. 
Initially, we performed a homology modeling calculation and secondary structure analysis using 
SWISS-MODEL and PSIPRED web servers, respectively. The C. d. cascavella sPLA2 homology 
model was built based on the template structure of crotoxin B from Crotalus durissus terrificus snake 
venom (PDB ID: 2QOG, chain C) [26], which shows 90% sequence identity. According to secondary 
structure prediction, the model of sPLA2 from C. d. cascavella showed the same structural motifs of 
PLA2: a β-wing, a hydrophobic channel, a calcium-binding loop, and C-terminal regions. 
Figure 4. (a) Effect of naringin on the sPLA2 antibacterial activity against Staphylococcus 
mutans. b) Observed structural modifications induced by sPLA2 and sPLA2-Nar on 









Figure 5. (a) CD spectra of native sPLA2 and sPLA2-Nar. Data over the range of  
185–300 nm are shown. The CD spectra are expressed in ellipticity units in millidegrees. 
(b) The mass measurement of native and naringin-treated sPLA2 by MALDI-TOFF mass 
spectrometry resulting in a molecular mass of 14,678.14 Da for native sPLA2 and 
14,687.34 Da for sPLA2-Nar. 
 
 
Structural information was also obtained using SAXS in which tertiary and quaternary structures of 
native sPLA2 and sPLA2-Nar were investigated. The scattering curves for both native and treated 
sPLA2 with the associated distance distribution functions, and Guinier and Kratky plots are shown in 
Figure 6. The Guinier plot shown in the inset of Figure 6a exhibits a linear relationship within the 
interval of 0.026 Å-1 < q < 0.058 Å-1 for sPLA2 and 0.026 Å-1 < q < 0.056 Å-1 for sPLA2-Nar, 
which are characteristic of monodisperse systems and from which the radius of gyration (Rg) of 23 Å 
and 24 Å were derived, respectively.  
 




Figure 6. Small Angle X-ray Scattering data plots. (a) Experimental scattering curves and 
Guinier region with its linear data fit. (b) Distance distribution functions, p(r). (c) Kratky 
plot. Black squares represent the SAXS data for the native protein (sPLA2, ~4 mg/mL), 
and the SAXS data for the protein after treatment with naringin (sPLA2-Nar, ~7 mg/mL) 
are shown as gray circles. 
 
 
The p(r) functions calculated with GNOM from the scattering curves are shown in Figure 6b. For 
both native sPLA2 and sPLA2-Nar, the Kratky plot exhibited a characteristic maximum of correctly 
enovelated proteins (Figure 6c). The radii of rotation calculated for several sPLA2 crystallographic 




models with different numbers of molecules in the asymmetric unit (ASU) (PDB ID: 1A2A, 1BJJ, 
2QOG, 1CL5, 1JIA, and 2OQD) using the program CRYSOL led to a regular dependency of Rg 
values with the number of molecules in the ASU: ~35 Å for eight, ~30 Å for six, ~25 Å for four, from 
18 to 24 Å for two, and from 13 to 14 Å for one molecule, suggesting that sPLA2 from C. d. cascavella 
in solution, before and after treatment with naringin, is composed of two polypeptide chains. 
Determination of the molecular weight with the web tool “SAXS MoW” confirmed that sPLA2 and 
sPLA2-Nar appear as dimers in solution at the concentrations evaluated, with an average molecular 
weight of ~28 kDa. The expected molecular weight based on the amino acid sequence of sPLA2 is 
28.9 kDa. Low resolution models recovered from scattering data showed an elongated shape as 
expected by the distance distribution functions asymmetric format (Figure 6b). In addition, envelope 
models of sPLA2-Nar were interestingly different from the native envelopes (Figure 7). 
Figure 7. Superimposition of the dimeric high resolution model for agkistrodotoxin sPLA2 
(PDB entry 1BJJ, chains A and E) is shown as a cartoon, and SAXS envelopes are shown 
in dark gray and light gray. (a) The native low resolution model obtained is shown in dark 
gray. (b) The envelope of the protein after treatment with naringin is shown in light gray. 
Envelopes (left) are rotated clockwise by 90° around the y- (middle) and z-axes (right). 
This figure was prepared using PyMOL (DeLano Scientific, San Carlos, CA, 
http://www.pymol.org). 
 




According to our models, naringin appears to induce a conformational modification of sPLA2 from 
C. d. cascavella. To interpret such envelopes, different dimer configurations of several sPLA2 
crystallographic models found in PDB were superimposed, including dimers formed by symmetric 
mates (results not shown). Using the program CRYSOL to compare the experimental scattering data 
and the scattering intensities computed from these models, the lowest discrepancy was found for the 
dimer made of chains A and E of agkistrodotoxin from Agkistrodon halys pallas venom (PDB ID 
1BJJ) [27]. Analysis of protein assemblies and interfaces using the PISA web server suggested that 
assembly of chains A and E of agkistrodotoxin is stable in solution, showing one of the highest 
ΔdissG, equal to 6.7 kcal/mol. 
Finally, the C. d. cascavella sPLA2 homology model obtained using the SWISS-MODEL web 
server was superposed onto chains A and E of the agkistrodotoxin dimer in an attempt to evaluate 
biochemical and structural alterations in sPLA2 after naringin treatment (Figure 8). This new dimeric 
assembly built in silico for C. d. cascavella sPLA2 was then used in the interpretation of the low 
resolution model bending due to naringin treatment. 
Figure 8. Stereo cartoon representation of the C. d. cascavella sPLA2 dimer modeled with 
SWISS-MODEL and built in silico based on the high resolution model of agkistrodotoxin 
sPLA2 (PDB entry 1BJJ, chains A and E. This figure was prepared using PyMOL (DeLano 
Scientific, San Carlos, CA, http://www.pymol.org). 
 




2.1. Enzymatic activity  
Polyphenolic compounds, such as naringin, have been characterized as highly specific and potent 
inhibitors of phospholipase A2 activity. This action of flavonoids and other polyphenolic compounds 
is attributed to an ability to bind the hydrophobic catalytic pocket of this enzyme, such as is found in 
morin, and umbelliferone incubated with sPLA2 [7,8]. In addition, it has been reported that the 
positions of the hydroxyl groups found in the flavonoid structure (3′- and 4′-position in the B-ring) are 
important for selective inhibition of sPLA2 activity of group II molecules, such as PLA2s from 
Crotalus durissus ssp and Bothrops sp [5]. 
According to our results, the enzymatic activity of native sPLA2 from C. d. cascavella was strongly 
reduced after treatment with naringin, almost to the same level as the potent sPLA2 enzymatic 
inhibitor p-BPB (Figure 2a). These findings suggest that naringin and p-BPB may inhibit sPLA2 
activity in a different way. Crystallographic studies of sPLA2 from Bothrops jararacussu venom have 
shown that pBPB interacting with His-48 an important residue involved with the the catalytic triad, 
whereas our results suggest that naringin modified several aromatic residues in the hydrophobic 
channel [28].  
2.2. Pharmacological properties 
In addition to the enhanced decrease in catalytic activity, sPLA2 inhibitors recognize 
pharmacological sites of such enzymes, consequently affecting their pharmacological action [29]. As 
our studies showed, chemical treatment of sPLA2 with naringin reduced some pharmacological 
effects, including myotoxicity (Figure 2b), neurotoxicity (Figure 2c), pro-platelet aggregation activity 
(Figure 2d), and edema formation (Figure 3a), which were induced by native sPLA2 in comparison 
with the same assays performed with the inhibitor p-BPB. 
One possible explanation for the lack of association between pharmacological and enzymatic 
activities is that the chemical modification of some amino acids induced by naringin, in particular 
aromatic amino acids and histidines, affected the toxin’s ability to interact with the pharmacological 
receptor, but did not lead to abolishment of this function. Our results and those described by Cardoso 
et al. [30] demonstrate that enzymatic activity of sPLA2 is not crucial for pharmacological activities of 
this sPLA2 isolated from C. d. cascavella venom. 
In terms of edema formation, it is noteworthy that the pharmacological effect seems to not be 
correlated with the catalytic activity, and that when naringin was previously applied to animal 
hindpaws, strong inhibition of hind paw edema was seen (Figure 3b). Flavonoids and other organic 
compounds from plants, such as flavones and alkaloids, are known to inhibit the enzymatic activity of 
sPLA2 [2,3], as well as lipoxygenase/cyclooxygenase and citossolic PLA2, enzymes evolved in the 
inflammatory cascade [31]. We believe that sPLA2s are responsible for activating these inflammatory 
enzymes due to arachidonic acid release and initiation of the inflammatory process. Thus, when 
naringin is previously injected, it inhibits these enzymes and prevents edema formation.    
This complementary assay suggests that unlike other pharmacological properties, the edema 
induced by sPLA2 is dependent on membrane phospholipids hydrolysis generating pharmacologically 
active lipids. On the other hand, the pharmacological modes of action of sPLA2 on myotoxicity, 
neurotoxicity, and platelet aggregation are not completely related to the enzymatic activity but may be 




involved in the ability of specific sPLA2 molecular regions to recognize pharmacological sites on the 
cells, as proposed by Cardoso et al. [30] for crotoxin, a PLA2 from Crotalus durissus terrificus venom. 
The antibacterial property induced by native sPLA2 from C. d. cascavella appears to be a toxic 
effect that is more closely related to the enzymatic activity, as was found for other sPLA2 that employ 
enzymatic catalysis for antibacterial function [32]. Although native sPLA2 showed high phospholipase 
function, bacterial cell membrane damage was significant. After naringin treatment and pronounced 
reduction of catalytic activity, the level of lysis was also decreased (Figure 4). Thus, abolishing or 
altering the sPLA2 enzymatic apparatus led to a significant loss of antibacterial activity by sPLA2 
from C. d. cascavella venom. 
2.3. Chemical and structural modifications 
The observed UV absorption modification after sPLA2 treatment with naringin can be mainly 
attributed to chemical changes in the aromatic amino acid residues and histidines of this enzyme, as 
verified previously by Iglesias et al. [7]. In addition, mass spectrometry analysis demonstrated that the 
chemical shift induced by naringin was discrete, not indicating an attachment of naringin to the sPLA2 
structure. The same result was found in previous studies of sPLA2 treated with umbelliferone [8]. 
CD spectroscopy showed that naringin treatment induced considerable alteration in the CD signal of 
sPLA2 as a consequence of modifications of mainly the α-helix. Helical structures in sPLA2 are 
responsible for forming the hydrophobic channel [18], which is occupied by the acyl chains of the 
substrate when bound, positioning the cleavage center towards the catalytic residues and forming an 
aperture to the external surface. In class I and II sPLA2s, when no substrate is bound, the hydrophobic 
channel is filled with ordered water molecules [33]. Therefore, in addition to our spectroscopic 
analyses, structural characterization reports suggest that naringin predominantly acted in the 
hydrophobic channel of sPLA2 from C. d. cascavella. 
Although side-chain orientation is still a main challenge in determining protein structures from a 
known sequence [34], methods based on rotamer libraries [35] have improved the prediction reliability 
in terms of side-chain torsional angles for preferred conformations [34]. However, amino acid side-
chains in both crystallographic and molecular modeling models are known to differ from those in 
physiological conditions [36]. From this point of view and considering the results derived from our 
current work, the definition of the molecular region where naringin acts is more important than 
addressing specific interactions and the most probable biologically active side-chain conformations of 
the important amino acids. 
2.4. Dimer models in solution for sPLA2 from C. d. cascavella  
Structural analyses of native sPLA2 and sPLA2-Nar performed by SAXS indicated that both 
samples behave as dimers in solution. Using high sequence identity snake venom sPLA2 
crystallographic models to interpret our low resolution models, we observed that C. d. cascavella 
dimers presented a new extended configuration that has never been seen for PLA2 in solution. 
We also verified that treatment with naringin induced conformational changes in sPLA2 with a 
clear bending of the dimer. Although unsuccessful, several attempts to model this bent dimer were 
performed, employing rigid body modeling and flexible docking. However, the interpretation of the 




SAXS model based on the C. d. cascavella homology model superimposed on the agkistrodotoxin 
crystallographic “dimer” (PDBID: 1BJJ, chains A and E) enabled identification of the aromatic amino 
acids, histidine and serine, of C. d. cascavella that are present at the dimer interface (Figure 8). These 
interfacial residues correspond to those affected by the action of naringin, and thus, the chemical 
modification caused by naringin must be responsible for the conformational change observed in the 
dimer configuration after naringin treatment. 
It has been reported that the dimerization of snake venom sPLA2 is a common event that strongly 
increases the enzymatic activity of sPLA2 in solution and determines the allosteric behavior of PLA2 
from Crotalus durissus ssp and Bothrops sp [13,37-40]. Our low resolution models for sPLA2 and 
sPLA-Nar allow us to suggest that in addition to chemical, secondary, and tertiary modifications 
induced by naringin in sPLA2 from C. d. cascavella, dimer bending may have reduced the possible 
enzymatic allosteric effect presented by this protein. 
3. Experimental 
3.1. Venom, animals and reagents 
Venom from C. d. cascavella was kindly donated by the Institute of Butantan (São Paulo, Brazil). 
Naringin was obtained from Sigma Co., Ltd. (USA). Solvents, chemicals, and reagents used in protein 
purification and characterization were of HPLC grade or higher and were acquired from Sigma-
Aldrich chemicals, Merck (USA), and Bio-Rad (USA). Male and female Wistar rats (120–150 g) and 
Swiss mice (18–20 g) used in the pharmacological assays were obtained from the Multidisciplinary 
Center of Biological Investigations (CEMIB-UNICAMP). All animal experiments were approved by 
the State University of Campinas Ethics Committee (São Paulo, Brazil). 
3.2. Purification of sPLA2 from Crotalus durissus cascavella venom  
Whole venom was first fractionated as previously described by Oliveira et al. [41]. Dried venom 
(45 mg) was dissolved in ammonium bicarbonate buffer (0.2 M, pH 8.0) and clarified by 
centrifugation (4,500 g, 1 min). The supernatant was injected onto a molecular exclusion HPLC 
column (Superdex 75, 1 × 60 cm, Pharmacia), and the chromatographic run was developed with a flow 
rate for fraction elution of 0.2 mL/min. Absorbance was monitored at 280 nm. The separated crotoxin-
like fraction was immediately lyophilized. The crotoxin-like fraction was then subjected to reverse 
phase chromatography using a μ-Bondapack C18 column (0.39 × 30 cm) with a flow rate for fraction 
elution of 1 mL/min. The chromatography was monitored at 280 nm. sPLA2 from C. d. cascavella was 
eluted using a non-linear gradient with buffer A (0.1% of trifluoroacetic acid in Milli-Q water) and 
buffer B (acetonitrile 66% in buffer A). The resulting PLA2 was termed sPLA2, and its purity was 
evaluated by Tricine SDS-PAGE and mass spectrometry on a MALDI-TOF mass spectrometer, as 
previously described by Toyama et al. [37,42]. 
3.3. Incubation of sPLA2 with naringin and purification of modified sPLA2 
The incubation of sPLA2 with naringin (mol:mol) was according to procedures described by 
Iglesias et al. [7]. Naringin was dissolved in dimethyl sulphoxide (DMSO), and its concentration 




during incubation with sPLA2 never exceeded 1%. Purified sPLA2 (1.5 mg, 100 nmol/mL) was 
dissolved in 1 mL of water. After complete homogenization, 10 µL of naringin solution (100 nmol) 
was added and incubated for 60 minutes in a water bath at 37 °C. Samples (200 µL) were loaded onto 
a preparative reverse phase HPLC column to separate the modified sPLA2 (sPLA2-Nar) from 
naringin. Samples were eluted using a discontinuous gradient of buffer (66.6% acetonitrile in 0.1% 
TFA) at a constant flow rate of 2.0 mL/min. The chromatographic run was monitored at A280 nm. In 
addition to the chemical modification with naringin, another modification with p-BPB was carried out 
according to the protocol described by de Castro et al. [43] and Hernandez-Oliveira et al. [44]. 
3.4. Measurement of sPLA2 oxidation 
Oxidation of sPLA2 after incubation with naringin was determined by measuring the absorption 
spectra of sPLA2 and sPLA2-Nar using wavelengths ranging from 200 to 300 nm. The 
chromatographic run was performed utilizing a Waters HPLC, with a 991 photodiode array detector 
(PDA 991, Waters) to record the absorption spectra of the samples. Detection was carried out at A214 
nm, with peak scanning between 190 and 310 nm (3-nm steps). In addition, chemical modification of 
the amino acid residues of sPLA2 in the presence of naringin was evaluated by amino acid analysis. 
For this analysis, approximately 1 nmol of purified protein (sPLA2 or sPLA2-Nar) was hydrolyzed 
with 6 N HCl (200 μL) in the presence of 10 μL of phenol. Amino acid hydrolysis was performed at 
106 °C for 24 h. Then, excess HCl was removed, and the hydrolyzed amino acids were redried with an 
aqueous solution of ethanol:water:triethylamine, 2:2:1 by volume. Post-column derivatization was 
performed with an aqueous solution of phenylisothiocyanate (ethanol-water-triethylamine- 
phenylisothiocyanate, 7:1:1:1 by volume). Both samples and amino acid standards were derivatized 
using a PICO-TAG amino acid analyzer system. The analysis of the phenylthiohydantoin-amino acid 
was also carried out using a PICO-TAG amino acid analyzer (Waters). 
3.5. Measurement of sPLA2 activity 
sPLA2 activity was measured following protocols described by Rigden et al. [45] and modified by 
Toyama et al. [37] in 96-well plates, using 4-nitro-3-octanoyloxybenzoic acid (4N3OBA, BIOMOL, 
USA) as substrate. Enzyme activity, expressed as the initial velocity of the reaction (Vo) was 
calculated based on the increase in absorbance after 20 minutes. All assays were performed with 
absorbance at 425 nm using a SpectraMax 340 multiwell plate reader (Molecular Devices, Sunnyvale, 
CA). After addition of native or naringin-treated sPLA2 (20 μg), the reaction mixture was incubated 
for up to 40 minutes at 37 °C, and absorbance was read at 10-minute intervals. 
3.6. Myotoxic activity 
Creatine kinase (CK) was assayed using the CK-NAc kit (Laborlab). Native sPLA2, sPLA2-Nar, or 
sPLA2 treated with p-BPB (sPLA2-p-BPB) (1 µg/µL in 50 µL) was injected into the left 
gastrocnemius muscle of male Wistar rats (90–110 g; n = 6). Control rats received an equal volume of 
0.15 M NaCl. After 3 hours, the rats were anesthetized, and blood was collected from the abdominal 
vena cava into tubes containing heparin as an anticoagulant. The plasma was stored at 4 °C for a 
maximum of 12 hours before assaying. The amount of CK was then determined using 4 µL plasma, 




which was incubated for 3 minutes at 37 °C with 1.0 mL of the reagent according to the kit protocol. 
Activity was expressed in U/L. 
3.7. Neurotoxic effect assay  
Male chicks (4–8 days old) were killed with ether, and the biventer cervicis muscle was removed 
[46,47] and mounted under a resting tension of 1 g in a 4-mL organ bath containing aerated (95% O2 + 
5% CO2) Krebs solution (pH 7.5, 37 °C) in mM: 118.7 NaCl, 4.7 KCl, 1.88 CaCl2, 1.17 KH2PO4, 
1.17 MgSO4, 25.0 NaHCO3, and 11.65 glucose. A bipolar platinum ring electrode was placed around 
the tendon, which ran the length of the nerve trunk supplying the muscle. Indirect stimulation was 
applied with a Grass S4 stimulator (0.1 Hz, 0.2 msec, 3–4 mV). Muscle contractions and contractures 
were recorded by connecting the preparation to a force displacement transducer (Narco Biosystems 
Inc.) coupled to a Gould RS 3400 recorder. Contractures to exogenously applied acetylcholine (ACh, 
55 or 110 µM for 60 seconds) and KCl (5 mM for 120–130 seconds) were obtained in the absence of 
nerve stimulation prior to the addition of modified and non-modified sPLA2 (10 µg/mL) at the end of 
the experiment. The preparations were allowed to stabilize for at least 20 minutes before the addition 
of ACh or KCl and a single concentration (10 µg/mL) of the compounds. 
3.8. Platelet aggregation studies 
Platelet aggregation activity was measured following methods described by Fonseca et al. [48]. 
Venous blood was collected following informed consent from healthy volunteers who denied taking 
any medication in the previous 14 days. Blood was collected with a two-syringe technique using 
polypropylene syringes and 19-gauge needles, and was immediately transferred into polypropylene 
tubes containing one-tenth final volume of 3.8% trisodium citrate. After removing the platelet-rich 
plasma, the remaining blood was prepared by centrifugation of citrated blood at 200 g for 10 min. 
Washed platelets were obtained from the residue by centrifugation of citrated blood at 1,500 g for  
20 min. Platelets were incubated for 1 hour at room temperature to recover their sensitivity to 
aggregating agents. Platelet counts were performed on a Coulter S Plus apparatus (Coulter Electronics, 
Hialeah, FL) or with phase-contrast microscopy. Platelet aggregation was carried out using 400 μL of 
the washed platelets solution in a cuvette and incubated at 37 °C with constant stirring. 
The desired concentration of protein was added 3 minutes prior to the addition of platelet 
aggregation inducers (thrombin for washed platelets). Subsequently, the aggregation was recorded for 
5–10 minutes with an aggregometer (Payton Scientific Instruments, Inc, Buffalo, NY). Aggregation 
experiments were performed with sPLA2 or sPLA2-Nar in concentrations of 10 μg in a final volume of 
20 μL. 
3.9. Paw edema assay 
Male Wistar rats (120–150 g) were anaesthetized with halothane (inhaled). Hind paw edema was 
induced by a single subplantar injection of native sPLA2 or sPLA2-Nar (10 μg per paw). Paw volume 
was measured immediately before the injection of the drugs and at selected times thereafter (30, 60, 
90, 120, 180, and 240 minutes) using a hydroplethysmometer (model 7150, Ugo Basile, Italy). All 
drugs were dissolved in sterile saline solution (0.9%). Results were expressed as the increase in paw 




volume (mL) calculated by subtracting the basal volume. When desired, the area under the time–
course curve (AUC) was also calculated (trapezoidal rule), and the results were expressed as the total 
edema volume (mL per paw). 
Thus, three groups of rats (n = 4 per group) were injected (i.p.) with dexamethasone or naringin  
(3.0 mg/kg) 30 minutes before the injection of native sPLA2 (10 μg per paw). Each rat received  
0.1 mL of drug. Dexamethasone and PBS were used as controls to evaluate the anti-inflammatory 
effect of naringin.  
3.10. Antibacterial activity  
The antibacterial activity was assayed as described by Santi-Gadelha et al. [49], and structural 
modification was done according to protocols described by Toyama et al. [50]. Xanthomonas 
axonopodis pv. passiflorae (Gram negative) and Streptococcus mutans (Gram positive) cells were 
harvested from fresh agar plates and suspended in sterile distilled water (A600 nm = 3 × 108 
CFU/mL). Aliquots of bacterial suspension were diluted to 103 colony-forming units/mL (CFU/mL) 
and incubated with sPLA2 and sPLA2-Nar samples (75 μg/mL) for 60 minutes at 28 °C. Survival was 
assayed on nutrient agar (Difco) plates (n = 5). For both antibacterial assays, electron microscopic 
assessment of morphologic alterations was performed in the absence (control) or presence of sPLA2 or 
sPLA2-Nar. 
Bacterial samples were centrifuged, recovered, fixed with 4% glutaraldehyde in buffer A (0.1 M 
cacodylate buffer, pH 7.4) for 1 h at 4 °C, embedded in 3% low-melting temperature agarose (Sea 
Plaque, FMC Corp.), and stored for 12 h in fixative at 4 °C. Agarose pellets were immersed in fixative 
for 2 h at 25 °C, washed three times for 10 minutes with buffer A, and fixed with 1% osmium 
tetraoxide for 2 hours at 25 °C. Sections were washed three times, dehydrated in increasing 
concentrations of ethanol, and embedded in Epon resin. Polymerization occurred at 60 °C for 48 hours, 
and ultra-thin sections were prepared with a Sorvall MT2 ultramicrotome. Sections were placed on 
grids and stained with 2% uranyl acetate for 15 minutes, followed by 2.6% lead citrate for 15 minutes. 
Samples were observed under a LEO 906 transmission electron microscope operating at 40–100 kV. 
3.11. Circular dichroism (CD) spectroscopy 
Native and sPLA2 modified with naringin were dissolved in phosphate buffer (10 mM, pH 7.4) to a 
final concentration of ~7 μM and ~4 μM for sPLA2 and sPLA2-Nar, respectively. Samples were 
transferred to quartz cuvettes with an optical path length of 1 mm. CD spectra between wavelengths 
185–300 nm were measured with a JASCO 710 apparatus using a bandwidth of 1 nm and a response 
time of 2–4 seconds. Scans were collected for each sample, and all spectra were corrected by 
subtraction of buffer blanks. Comparison of spectra was performed after concentration and optical path 
length normalization in terms of molar CD. 
3.12. Mass spectroscopy 
The molecular mass of sPLA2 and sPLA2-Nar were determined by matrix-assisted laser desorption 
ionization-time-of-flight (MALDI-TOF) mass spectrometry using a Voyager-DE PRO MALDI-TOF 
mass spectrometer (Applied Biosystems). One microliter of samples (sPLA2 and sPLA2-Nar) in 0.1% 




TFA was mixed with 2 µL of the matrix a-cyano-4-hydroxycinnamic acid, 50% acetonitrile, and 0.1% 
TFA (v/v). The matrix was prepared with 30% acetonitrile and 0.1% (v/v) TFA. Ion masses were 
determined with an accelerating voltage of 25 kV, with the laser operated at 2,890 µJ/com2, with a 
delay of 300 nanoseconds, and in the linear analysis mode. 
3.13. Small angle X-ray scattering (SAXS) 
SAXS measurements were carried out at the D02A-SAXS2 beamline of the Brazilian Synchrotron 
Light Laboratory [51]. Samples were kept at 4 °C in the sample cell [52], and data acquisition was 
performed taking several 600-second frames for each sample, which allowed for the control of any 
possible radiation damage and improved statistical errors. Data were collected at a sample-to-detector 
distance of 985.7 mm using a MAR CCD detector (MAR Research) with X-rays at a wavelength of 
1.488 Å, to cover q values ranging from 0.013 to 0.34 Å-1, where q, the moment transfer vector, is 
defined as q = 4πsinθ/λ. Different concentrations of sPLA2 were measured to assess aggregation 
[53,54] and interparticle interference effects. The best data sets were collected for samples of native 
sPLA2 and sPLA2-Nar at ~4 mg/mL and ~7 mg/mL, respectively. 
Initial data treatment of the scattering intensities was performed using Fit2D software [55]. Data 
were reduced to a 1D scattering profile and normalized according to intensity and sample attenuation. 
The net scattered X-ray intensities for the proteins were determined by subtracting a normalized buffer 
blank from each protein data set. Different frames for each sample were inspected and averaged using 
the program PRIMUS [56]. Distance distribution functions, p(r), and radius of gyration, Rg, were 
evaluated by the indirect Fourier transform method included in the program GNOM [57]. 
The Rg value was also estimated using Guinier analysis [58] in which the ln of I(q) was plotted 
against q2 to yield a straight line whose slope is proportional to Rg. Additional analysis was performed 
by plotting Iq2 against q (Kratky plot), which allows the evaluation of the degree of protein 
globularization [59]. The shape of the Kratky plot is sensitive to the conformational state of the 
macromolecule in solution. Globularly folded macromolecules have bell-shaped curves, whereas for 
completely unfolded states, a plateau or a slightly increasing function in the larger q range is observed 
[60]. Estimation of the molecular weight of sPLA2 and sPLA2-Nar in solution was performed with a 
relatively simple method included in the “SAXS MoW” web tool (http://www.ifsc.usp.br/ 
~saxs/saxsmow.html), which is based on the invariant Q calculated from the Kratky plot [61]. 
Low resolution envelopes were restored from the scattering curves using the ab initio procedure 
included in the program GASBOR [62]. In this program, dummy residue models were generated by a 
random-walk Cα chain and folded in a way that minimizes the discrepancy between the calculated 
scattering curve from the model and the experimental data. To increase the reliability of the results, 
final models were obtained with the program DAMAVER [63] using a spatial average of 50 
independent models. To clarify the visualization, the average model was represented by a surface-
calculated model using the program NCSMASK [64]. Superimpositions of crystallographic structures 
of several PLA2s found in the Protein Data Bank (PDB, www.rcsb.org) and the most probable SAXS 
models derived from DAMAVAVER were done using the program SUPCOMB [65]. Crystallographic 
sPLA2 models used in the interpretation of the low resolution models were chosen based on the 
smallest discrepancy (Chi) between the experimental scattering data and the scattering intensities 




computed for these models using the program CRYSOL [66]. In addition, rigid body modeling with 
the program SASREF [67] and flexible docking with the program package SITUS [68] were 
performed, aiming for the best interpretation of the SAXS envelopes. 
3.14. Additional computational analysis 
Automated comparative homology modeling using the SWISS-MODEL web server [69] 
(http://swissmodel.expasy.org//SWISS-MODEL.html) was employed to generate an atomic coordinate 
model for C. d. cascavella sPLA2. PSIPRED [70,71] was used for secondary structure prediction 
(http://bioinf.cs.ucl.ac.uk/psipred/). Protein assemblies and interfaces analyses were performed with 
the PISA web server [72] (http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html). 
3.15. Statistical analyses 
Results are reported as the means ± S.E.M. of n experiments. The significance of differences 
between means was assessed by an analysis of variance, followed by a Dunnett’s test when several 
experimental groups were compared with the control group. The confidence limit for significance  
was 5%. 
4. Conclusions  
According to our results, the enzymatic activity of native sPLA2 from C. d. cascavella was strongly 
reduced after treatment with naringin, almost to the same level as the potent sPLA2 enzymatic 
inhibitor p-BPB (Figure 2a). These findings suggest that naringin and p-BPB may inhibit sPLA2 
activity in a different way. Crystallographic studies of sPLA2 from Bothrops jararacussu venom have 
shown that pBPB interacting with His-48 an important residue involved with the the catalytic triad, 
whereas our results suggest that naringin modified several aromatic residues in the hydrophobic 
channel [28].  
Based on the chemical modification and CD experiments, naringin interacted predominantly in the 
sPLA2 molecular region with the highest concentration of aromatic amino acid residues (histidines and 
serines, shown in Figure 8), which are found at the bottom of the hydrophobic channel (between the N-
terminus and the α2- and α3-helices) and the β-wing motif. In addition to containing the majority of 
the modified amino acid residues, the hydrophobic channel is also the sPLA2 structural domain 
responsible for catalysis, comprising the catalytic triad: Gly31, His47, and Asp89 according to the 
sPLA2 amino acid sequence (shown in Figure 8). Thus, chemical and structural modifications in this 
enzymatic region by naringin may be the main reason for the inhibition of enzymatic activity and the 
correlated edema formation and antibacterial functions of sPLA2 from C. d. cascavella. 
The structural studies we performed permitted identification of the probable region in C. d. 
cascavella sPLA2 that was affected by naringin. This region seems to be responsible for some of the 
pharmacological properties of this enzyme. Chemical and structural modifications also interfered with 
the active site of sPLA2 and affected its possible enzymatic allosteric behavior. 
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